NCT05580562 2026-04-16
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
29 trialsNCT02392572 2026-04-14
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05542407 2026-01-29
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT03932643 2026-01-20
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
University of Nebraska
Phase 1 Completed
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04055649 2025-06-18
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03099499 2024-12-24
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT03485729 2024-12-24
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT04629209 2023-11-24
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT03791398 2023-02-17
379
Brown University
Phase 1/2 Terminated
NCT03394027 2022-08-23
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05392374 2022-05-26
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
Jazz Pharmaceuticals
No longer available
NCT02420795 2022-04-04
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03134131 2022-03-14
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
No longer available
NCT03733119 2022-03-10
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT02609230 2021-06-04
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Fox Chase Cancer Center
Phase 1 Completed
NCT04854044 2021-05-12
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT02250781 2019-05-22
Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT02324621 2019-05-22
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed